导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.19% | 2748/4763 |
| 近一周 | -1.81% | 2889/5452 |
| 近一月 | -3.51% | 2575/5409 |
| 近一季 | -6.72% | 2519/5219 |
| 近半年 | -2.17% | 2031/4908 |
| 近一年 | 1.49% | 2465/4388 |
| 近两年 | 45.21% | 1659/2951 |
| 近三年 | 27.72% | 1178/2250 |
| 成立以来 | 39.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.54% 3273/4961 |
12.14% 2221/5312 |
- - |
- - |
| 2025 | 19.53% 2209/4813 |
-0.99% 2517/3635 |
2.16% 1799/4076 |
17.96% 2385/4524 |
0.17% 2158/4813 |
| 2024 | 16.16% 842/3463 |
2.78% 703/2808 |
-1.11% 938/3014 |
16.16% 1518/3129 |
-1.62% 1773/3463 |
| 2023 | -8.87% 1069/2656 |
4.32% 982/2280 |
-3.84% 925/2385 |
-2.89% 783/2515 |
-6.45% 1781/2655 |
| 2022 | -19.12% 802/2207 |
-13.81% 846/1919 |
6.63% 646/2016 |
-13.60% 929/2113 |
1.86% 1115/2208 |
| 2021 | -2.62% 863/1822 |
-2.93% 730/1255 |
4.36% 896/1330 |
-5.40% 802/1466 |
1.62% 860/1822 |
| 2020 | 29.45% 538/1250 |
-9.27% 666/1028 |
13.26% 632/1067 |
11.34% 460/1164 |
13.14% 389/1184 |
| 2019 | - - |
- - |
- - |
0.65% 493/850 |
6.81% 543/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达沪深300ETF联接C VS. 长安沪深300非周期A(740101) |